Investors Urged to Join Class Action Against Cerevel Therapeutics Over Securities Fraud Allegations

Potential Securities Fraud Case Against Cerevel Therapeutics: An Overview

On April 14, 2025, the Schall Law Firm, known for its advocacy in shareholder rights, issued a reminder for investors concerning a pending class action lawsuit against Cerevel Therapeutics Holdings, Inc. This lawsuit is based on alleged violations of federal securities laws, specifically sections 10(b) and 20(a) of the Securities Exchange Act of 1934, alongside Rule 10b-5 established by the U.S. Securities and Exchange Commission.

Background of the Case

The focus of the lawsuit is on investors who purchased shares of Cerevel, traded under the NASDAQ symbol CERE, during the period from October 11, 2023, to August 1, 2024. Additionally, shareholders who were eligible to vote on the merger between Cerevel and AbbVie Inc. as of January 8, 2024, and those who sold shares around the time Bain Capital Investors, LLC acquired shares on October 16, 2023, are particularly encouraged to reach out. The deadline for potential participants is June 3, 2025.

Allegations of Misleading Statements

The core allegations state that Cerevel provided false and misleading information regarding a secondary stock offering and a proxy statement which impacted investor decisions. The secondary stock offering, organized by Bain Capital and Pfizer on October 16, 2023, was believed to be part of a scheme to raise funds at a discounted price just days before it was publicly disclosed that AbbVie intended to acquire Cerevel for $45 per share. This acquisition, which was revealed merely 51 days after the offering, was almost double the price at which the secondary offering was made. Thus, the lawsuit argues that the public statements made by the company were inherently misleading, leading to significant losses for investors once the truth emerged.

Contacting the Schall Law Firm

The Schall Law Firm is representing affected investors globally, encouraging individuals who believe they have suffered financially due to Cerevel's actions to come forward. Investors are urged to contact Brian Schall directly at their Los Angeles office or through the firm’s official website for a free discussion regarding their rights.
While the class action has yet to receive certification, the firm emphasizes the importance of participation to recover potential losses. Those who choose not to take action will remain absent class members, meaning they will not be able to claim any recoveries should the lawsuit succeed.

Join the Case

This situation highlights the importance of vigilance within the investor community, especially concerning corporate actions that may impact shareholder value. The Schall Law Firm’s efforts to advocate for investors underscore the extensive challenges that can arise when companies allegedly obscure critical business dealings from their shareholders. If you are a Cerevel shareholder who believes you may be affected, now is the time to act—consider reaching out well before the upcoming deadline to ensure your voice is heard in this important legal battle.